{
    "clinical_study": {
        "@rank": "14835", 
        "arm_group": [
            {
                "arm_group_label": "Period I FK949E", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Period I placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Period II FK949E", 
                "arm_group_type": "Experimental", 
                "description": "Patients who completed the treatment Period I"
            }
        ], 
        "brief_summary": {
            "textblock": "In period I, the treatment effect of FK949E will be compared with that of placebo in a blind\n      manner in bipolar disorder patients with major depressive episodes.  In period II, long-term\n      safety and efficacy of FK949E will be evaluated."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study consists of two part.  In Treatment Period I, FK949E or placebo will be\n      administered orally in a blind manner to bipolar disorder patients with major depressive\n      episodes, with the aim of evaluating the superiority of FK949 over placebo and the dose\n      response of two doses of FK949E based on changes in Montgomery-Asberg Depression Rating\n      Scale (MADRS) total score. In Treatment Period II, the long-term safety, efficacy and\n      parmacokinetics of FK949E will be evaluated in patients who have participated in the study\n      and completed the Treatment Period I."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of bipolar I or II disorder as specified in the DSM-IV-TR, with a major\n             depressive episode\n\n          -  The Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more and\n             HAM-D17 depressed mood score of 2 points or more\n\n          -  Able to participate in the study with understanding of and compliance with subject\n             requirements during the study in the investigator's or subinvestigator's opinion\n\n        Exclusion Criteria:\n\n          -  Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar\n             disorder, within the last 6 months before informed consent\n\n          -  Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect\n             patient's current mental status\n\n          -  The Young Mania Rating Scale (YMRS) total score of 13 points or more\n\n          -  Nine or more mood episodes within the last 12 months before informed consent\n\n          -  Lack of response to at least 6-week treatment with at least 2 antidepressants for the\n             current major depressive episode in the investigator's or subinvestigator's opinion\n\n          -  History of abuse or dependence of alcohol or substances other than caffeine and\n             nicotine\n\n          -  Treatment with a depot antipsychotic within the last 42 days before primary\n             registration\n\n          -  Unable to suspend mood stabilizers (lithium carbonate and/or sodium valproate),\n             lamotrigine, antipsychotics, or antidepressants from 7 days before secondary\n             registration\n\n          -  Unable to suspend antiepileptics (except lamotrigine and sodium valproate),\n             antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents,\n             cerebral ameliorators, antidementia agents, or anorectics, except those specified as\n             conditionally-allowed concomitant drugs, after primary registration\n\n          -  Electroconvulsive therapy within the last 76 days before primary registration\n\n          -  The current major depressive episode persisting for more than 12 months or less than\n             4 weeks before informed consent\n\n          -  A possible need of psychotherapy during the study period (unless the therapy has been\n             commenced at least 76 days before primary registration and been maintained on a fixed\n             level at fixed frequency)\n\n          -  Documented or suspected conditions such as renal failure, hepatic failure, serious\n             cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency syndrome\n             (AIDS) (or to be a carrier of hepatitis B, hepatitis C, or AIDS)\n\n          -  Concurrence of malignancy or history of cured malignancy within 5 years\n\n          -  Concurrence of uncontrolled hypertension (defined as a systolic blood pressure of 180\n             mmHg or more, or a diastolic blood pressure of 110 mmHg or more at primary\n             registration) or unstable angina that may worsen with the study or may affect the\n             study results based on the clinical judgment of the investigator or sub-investigator\n\n          -  Concurrence of hypotension (defined as a systolic blood pressure of less than 100\n             mmHg at primary registration) or orthostatic hypotension\n\n          -  History of transient, idiopathic orthostatic hypotension, with or without pre-syncope\n             symptoms or syncope, or a current condition susceptible to transient hypotension,\n             such as dehydration and decreased blood volume\n\n          -  Concurrent or previous history of cerebrovascular disease or transient ischemic\n             attack (TIA)\n\n          -  Abnormal laboratory or electrocardiographic findings considered clinically\n             significant in the investigator's or subinvestigator's opinion (in reference to grade\n             3 of the Adverse Drug Reactions Severity Grading Criteria [Notification No. 80 of the\n             Safety Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare dated\n             29 June 1992])\n\n          -  Participation in another clinical study or post-marketing study within the last 12\n             weeks before informed consent\n\n          -  History of quetiapine therapy during the current major depressive episode\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725308", 
            "org_study_id": "6949-CL-0021"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Period I FK949E", 
                    "Period II FK949E"
                ], 
                "description": "Oral", 
                "intervention_name": "FK949E", 
                "intervention_type": "Drug", 
                "other_name": "quetiapine"
            }, 
            {
                "arm_group_label": "Period I placebo", 
                "description": "Oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "FK949E", 
            "Major depressive episode", 
            "patients"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II/III Study of FK949E \u2014 Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes \u2014", 
        "overall_contact": {
            "email": "clinicaltrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, at 8 weeks after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725308"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "MADRS", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at 8 weeks after dosing"
            }, 
            {
                "measure": "Hamilton Depression Rating Scale (HAM-D17)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at 8 weeks after dosing"
            }, 
            {
                "description": "(Mania, Depression and Overall)", 
                "measure": "Clinical Global Impression-Bipolar-Severity (CGI-BP-S)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at 8 weeks after dosing"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and Labo-tests", 
                "safety_issue": "No", 
                "time_frame": "for 1 year"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}